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Background: Recent research indicates that sleep disturbances are common in persons with 
multiple sclerosis (MS), though research to date has primarily focused on the relationship 
between fatigue and sleep. In order to improve treatment of sleep disorders in MS, a better 
understanding of other factors that contribute to MS sleep disturbance and use of sleep medica-
tions in this population is needed.
Methods: Individuals with MS (N = 473) involved in an ongoing self-report survey study were 
asked to report on use of over-the-counter and prescription sleep medications. Participants com-
pleted the Medical Outcomes Study Sleep (MOSS) scale and other common self-report symptom 
measures. Multiple regression was used to evaluate factors associated with sleep problems and 
descriptive statistics were generated to examine use of sleep medications.
Results: The mean score on the MOSS scale was 35.9 (standard deviation, 20.2) and 46.8% 
of the sample had moderate or severe sleep problems. The majority of participants did not use 
over-the-counter (78%) or prescription (70%) sleep medications. In a regression model vari-
ables statistically significantly associated with sleep problems included depression, nighttime 
leg cramps, younger age, pain, female sex, fatigue, shorter duration of MS, and nocturia. The 
model explained 45% of the variance in sleep problems. Of the variance explained, depression 
accounted for the majority of variance in sleep problems (33%), with other variables explaining 
significantly less variance.
Conclusions: Regression results indicate that fatigue may play a minor role in sleep distur-
bance in MS and that clinicians should consider the interrelationship between depression and 
sleep problems when treating either symptom in this population. More research is needed to 
explore the possibility of under-treatment of sleep disorders in MS and examine the potential 
effectiveness of nonpharmaceutical treatment options.
Keywords: multiple sclerosis, sleep, depression, fatigue, nonpharmaceutical treatments, self-
medication
Introduction
Multiple sclerosis (MS) is a demyelinating and degenerative disease of the central 
nervous system that affects approximately 2.5 million people worldwide.1 Although 
the disease course may vary significantly among individuals, common symptoms of 
MS include changes in mobility, fatigue, spasticity, depression, pain, and cognitive 
decline.2 Recent research has emerged that suggests sleep disturbances are also com-
mon in individuals with MS, with approximately 50% of individuals reporting sleep 
problems.3,4 Treatment of sleep disorders in persons with MS is important because sleep 
dysfunction can potentially exacerbate other MS symptoms5 (eg, mental health prob-
lems) and has recently been shown to be an independent predictor of quality of life.6Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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In order to improve treatment of sleep disorders in MS, 
a better understanding of factors that contribute to MS sleep 
disturbance and use of sleep medications in this population 
is needed. Research to date has primarily focused on preva-
lence of sleep disorders3,4 and the relationship between sleep 
and fatigue in MS.7–12 While these studies have consistently 
shown that a relationship between sleep and fatigue exists 
in MS, sleep research from the general population and in 
other chronic conditions suggests that other factors, such as 
age, gender, and depression5,13,14 may play a significant role 
in sleep disturbance in MS as well. There is some evidence 
in the MS literature, primarily from descriptive studies and 
qualitative research, that muscle spasms, periodic limb 
movements, nocturia, psychiatric illness, and pain may also 
contribute to sleep disturbances in MS.11,15 However, to 
date studies in the MS literature have primarily examined 
the independent role of these factors in sleep, rather than 
in combination with fatigue or each other. In addition, no 
studies to date have examined the use of sleep medications 
in individuals with MS and associations between medication 
use and sleep outcomes.
Identifying factors that play a significant role in sleep 
disturbances in MS will contribute to improved MS care 
and treatment. Clinicians will be better able to target those 
factors most likely to contribute to disrupted sleep in their 
patient(s), and thus provide the treatment(s) most likely to 
improve sleep in their MS patients. In addition, as sleep has 
been shown to significantly impact overall health and quality 
of life,6 we believe a vital component of MS care consists of 
improving sleep for patients with difficulties and will signifi-
cantly contribute to improved quality of life. The objective of 
this study was therefore to examine the association between 
multiple demographic and disease characteristics with sleep 
problems using a multivariate regression approach. In addi-
tion, we sought to describe the use of sleep medications in 
this sample in order to better understand the prevalence of 
use in persons with MS.
Methods
research participants
Study participants were involved in an ongoing longitudinal 
study of self-reported health outcomes in MS, which has been 
described elsewhere.3,16,17 Participants were initially recruited 
through the Western Washington chapter of the National MS 
Society (NMSS) and initial letters of invitation were sent to 
7,806 persons from the NMSS mailing list, which primarily 
included individuals who self-identified with the NMSS as 
having MS. Of the 1,629 (20.8%) to respond, 1,597 were 
eligible for and indicated interest in participation. Eligible 
individuals were required to report having a definitive diag-
nosis of MS and be aged at least 18 years. 1,271 individuals 
completed the initial survey between November 2006 and 
September 2007, either on paper or via the Internet, and 
paper survey responders with missing data were called up 
to four times to collect data via phone. A subset of 562 was 
randomly selected from the original subject pool of 1,271 
to receive invitations to continue in the longitudinal survey 
study. The effectiveness of the randomization was explored 
and with the exception of ethnicity (noninvitees [98.5%] 
vs invitees [96.6%] were white; P = 0.03), no significant 
differences in demographics (age, gender, education, marital 
status, employment status) or disease characteristics (dis-
ease severity, duration, and relapsing type MS) were found 
between those invited to continue in the longitudinal study 
and not. Subsequent surveys were administered by mail 
every four months and participants received reminder let-
ters and phone calls two and four weeks postadministration, 
respectively. Participants were called up to four times to 
collect missing data for each survey. A total of 513 (91.3%) 
individuals completed the second survey at four months, 488 
(86.8%) completed the third survey at eight months, and 473 
(84.2%) completed the fourth survey at 12 months. Due to 
late response, a total of nine and four individuals were not 
invited to continue at the eight- and twelve-month survey 
time points, respectively. Data reported in this paper are 
cross-sectional from the fourth survey time point (completed 
twelve months after the initial survey) because questions rel-
evant to sleep had been included in this time point. All study 
procedures were approved by the Human Subjects Division 
at the University of Washington, and participants were paid 
$25 for completing each survey time point.
Measures
All measures were administered via self-report survey, and 
domains assessed primarily focused on the common symp-
toms of MS including pain, fatigue, depression, mobility 
changes, and sleep problems. Age, sex, and other demo-
graphic characteristics were also included for characteriza-
tion of the study sample.
Primary outcome measures
Sleep problems were measured using the 12-item Medical 
Outcomes Study Sleep18 (MOSS) scale, which is scored 
to yield six different sleep subscales and an overall sleep 
problems index (Sleep Problems Index II). Subscales are 
standardized to yield scores from zero to 100, with higher Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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scores on the Sleep Problems Index II and sleep disturbance 
subscales indicating more sleep problems or more sleep 
disturbance. The MOSS scale has been validated in large 
samples18,19 and a comparison of this sample with normative 
scores was completed previously.3
In order to evaluate use of medications for sleep, partici-
pants were asked to separately report if they currently take 
prescription or over-the-counter medications to help with 
difficulties sleeping. If they reported yes, they were asked to 
indicate how often they take these medications, and response 
options included “less than once a week”, “1–2 times a 
week”, “3–4 times a week”, and “every day”.
Covariate measures
Depression was assessed using the nine-item Patient Health 
Questionnaire20 (PHQ-9) depression module,21 which is a brief 
self-report diagnostic and severity measure of depression. 
Items are scored on a scale from zero to three and summed 
to obtain overall depression severity scores, with higher 
scores indicating more depressive symptoms. The PHQ-9 
has been extensively validated in multiple populations21–25 
and has been shown to have superior criterion validity for 
diagnosis of major depressive disorder compared with other 
depression screening questionnaires.26 The PHQ-9 contains 
one item that refers to sleep difficulties, which was omitted 
from this analysis to reduce spurious associations between 
depression scores and sleep problems in the analyses. Thus, 
depression scores ranged from 0–24 in this study.
The modified version of the Fatigue Impact Scale27,28 
(MFIS) was included to evaluate severity of fatigue. The MFIS 
is a 21-item scale developed by the United States National 
Multiple Sclerosis Society for measuring fatigue in MS, and 
contains three subscores in addition to an overall fatigue score. 
Items are scored from zero to four with total scores ranging 
from zero to 84 and higher scores corresponding to more 
fatigue. The MFIS has been shown to more comprehensively 
assess fatigue in MS than other fatigue measures.29
A self-report version of the Expanded Disability Status 
Scale (EDSS),30 a measure used to evaluate disease progres-
sion in MS, was also included in the survey. The self-report 
version has been shown to be highly correlated with the 
physician administered EDSS.30 Individuals were scored 
from #4.0 to $8.0 based on responses to the mobility sec-
tion of the EDSS. Individuals were categorized into minimal 
severity (#4.0) representing no mobility aid use, intermediate 
severity (4.5–6.5) representing unilateral or bilateral mobility 
aid use, and advanced ($7.0) severity representing primarily 
wheelchair use for mobility.
The domains of pain, restless legs, nocturia, nighttime 
leg cramps, and bed related immobility were assessed using 
single items. Pain was evaluated using an item adapted from 
the pain-intensity items of the Chronic Pain Grade scale.31 
Specifically, participants were asked “in the past week, how 
intense was your worst pain rated on a 0–10 scale where 
0 is ‘no pain’ and 10 is ‘pain as bad as can be.’” Numerical 
rating scales for pain intensity have demonstrated good psy-
chometric properties and are widely used in pain research.32 
A single-item rapid screener for restless legs was included to 
assess likelihood of restless leg syndrome. This single-item 
screener has been shown to have excellent sensitivity and 
specificity in a neurological clinical practice population.33 
To assess nocturia, participants were asked a single yes or 
no question, “do you usually get up to go to the bathroom 
in the night,” and if yes, how many times they got up on 
a typical night. For purposes of the regression individu-
als who got up at least twice to go to the bathroom in the 
night were considered as having problems with nocturia. 
Leg cramps and bed related immobility were assessed by 
asking participants how often they were bothered by the 
symptom on a typical week, and response options ranged 
from “never” to “almost always” on a five-point scale. The 
item stems to evaluate these two symptoms were specifi-
cally “leg cramps that interfere with your sleep” and “being 
unable to change your position easily on your own when 
lying in bed.” The nocturia, leg cramps, and bed mobility 
items were all created by the study authors after consulta-
tion with MS clinicians.
Data analysis
Descriptive statistics were generated to describe the sample as 
well as use of over-the-counter and prescription sleep medi-
cations. Mean scores with standard deviation on the MOSS 
Problems Index II and sleep disturbance subscales were 
calculated for each category of medication use and for the 
population as a whole. In order to statistically compare sleep 
scores between groups of medication users, individuals were 
categorized into one of three groups for both prescription and 
over-the-counter medications: never users, sometime users 
(,1 week up to 3–4 times/week), and always users (every 
day). Wilcoxen rank-sum tests were conducted to compare 
scores on the sleep problems index and sleep disturbance 
subscales between these three groups for both prescription 
and over-the-counter medication use. Because of concerns 
about multiple testing, a Bonferroni correction to the alpha 
level of 0.05 was used, resulting in a required P-value cutoff 
of less than 0.004 for statistical significance.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Linear regression modeling was completed to identify 
factors associated with sleep problems in this sample. The 
dependant variable was sleep problems as measured by 
the MOSS Sleep Problems Index II. Independent variables 
examined in the analyses were identified a priori through a 
literature search and discussions with MS physicians. Back-
wards multiple linear regression modeling was utilized and 
the initial full model included the following independent 
variables: current age in years, duration of MS in years, 
EDSS level, gender, fatigue, depression, pain, nocturia, bed 
mobility, nighttime leg cramps, and restless legs. Based on 
earlier research indicating that fatigue in MS is affected by 
depression, a depression-fatigue interaction term was also 
tested in the final model. Variables were removed from the 
full model sequentially based on their t-statistic, and only 
variables significant at the alfa level of 0.05 were included 
in the final model. Adjusted R2 contributions were also calcu-
lated for each variable independently to examine the variance 
explained in sleep problems by each variable independently 
beyond that explained by other variables already included in 
the model. This was done by ordering the variables accord-
ing to their t-score, removing the variable with the smallest 
t-value, and calculating the difference in model adjusted 
R2. This process was then repeated for each variable until 
only one variable remained in the model (depression was 
the final variable as it had the highest t-score). Unusual and 
influential data points as well as the regression assumptions 
of linearity, multicollinearity, normality of residuals, and 
homoscedasticity of residuals were thoroughly investigated. 
All assumptions were met and no unusual or influential data 
points were identified.
Results
The mean age of participants (N = 473) was 52.3 years and 
mean disease duration was 14.5 years. The large majority of 
participants were female (82.7%) and most were married or 
living with a significant other (68.3%). The mean score on 
the MOSS Sleep Problems Index II for the sample was 35.9 
(standard deviation [SD], 20.2) and on the sleep disturbance 
subscale it was 32.6 (SD, 25.9). Of variables included in the 
regression model, restless leg-like symptoms were endorsed 
most often (50.7%), followed by nocturia (36.0%), leg 
cramps (35.4% report sometimes or greater), and bed mobil-
ity problems (27.1% report sometimes or greater). Additional 
sample characteristics can be found in Table 1.
The majority of participants did not use over-the-counter 
(78%) or prescription (70%) sleep medications (Table 2). 
Individuals who used prescription medications tended to use 
them every day with 19.5% of the sample reporting everyday 
use and only 10.6% reporting intermittent use. In contrast, 
only 7.8% of the sample used over-the-counter medications 
every day while 14.2% of the sample reported intermittent 
use. In statistical comparisons of scores between never, some-
time, and always users of prescription medications we found 
that “never users” had significantly lower sleep problems and 
sleep disturbance scores than either “sometime” or “always 
users” on both subscales (P # 0.0001 for all comparisons). 
For over-the-counter medication users, “never users” had 
significantly lower sleep problems scores (P = 0.002) than 
“always users” and lower sleep disturbance scores than both 
“sometime” (P = 0.002) or “always” (P , 0.0001) users. No 
tests between “sometime” and “always users” were statisti-
cally significant after Bonferroni adjustment. Additional 
information on sleep problems and sleep disturbances scores 
can be found in Table 2.
Variables statistically significantly associated with sleep 
problems included depression, nighttime leg cramps, younger 
age, pain, female sex, fatigue, shorter duration of MS, and 
nocturia (Table 3). EDSS level, bed mobility, and restless 
legs were not significantly associated and were dropped from 
the model. The fatigue-depression interaction term was also 
Table 1 study participant characteristics (n = 473)
Mean ± SD 
n (%) 
sleep problems (MOss sleep Problems index ii)  35.9 ± 20.2
sleep disturbance (MOss sleep Disturbance subscale) 32.6 ± 25.9
Age (years) 52.3 ± 10.9
Female 391 (82.7)
Duration of Ms (years)  14.5 ± 9.9
EDss category
  Mild (#4.0) 145 (30.7)
  Moderate (4.5–6.5) 240 (50.9)
  severe ($7.0) 87 (18.4)
Education level
 # high school/gED  68 (14.4)
  Technical/some college  180 (38.1)
  Bachelors degree  140 (29.6)
  graduate degree 85 (18.0)
Married 323 (68.3)
Depression (PhQ-9)  6.5 ± 5.25
Fatigue (MFis)  38.8 ± 17.9
Pain 4.7 ± 3.3
nocturia 170 (36.0)
restless leg-like symptoms  240 (50.7)
Leg cramps  165 (35.4)
Bed mobility problems  127 (27.1)
Abbreviations: EDss, Expanded Disability status scale; gED, general Education 
Development test; MFIS, Modified Fatigue Impact Scale; MOSS, Medical Outcomes 
study  sleep;  Ms,  multiple  sclerosis;  PhQ-9,  Patient  health  Questionnaire;  sD, 
standard deviation.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
103
Beyond fatigue in Ms sleep problems
dropped from the final model due to statistical insignificance. 
Individual R2 contributions indicate that depression explains 
the majority of variance in sleep problems (33%), with other 
variables explaining significantly less variance. Pain, age, and 
leg cramps explain approximately 3% additional variance 
each with the remaining variables, including fatigue, explain-
ing less than 1%. The final model was highly significant with 
a final model adjusted R2 of 0.45.
Discussion
Until recently, little attention has been given to the question 
of sleep adequacy in MS, and the majority of sleep research 
in MS has focused on the relationship between fatigue and 
sleep.7–12 Sleep has been identified as a significant problem 
for this population with approximately 50% of persons 
reporting problems3,4 and research is needed to examine 
factors that can mitigate the impact of poor sleep on quality 
of life of people living with MS. This paper is a first step in 
this process. We have sought to identify the extent to which 
patients with MS manage their sleep through medications, 
and to identify potentially modifiable symptoms or factors 
which are associated with sleep difficulties.
In general, little is known about medication use for sleep in 
either the general population or within specific disease groups. 
However, two studies on sleep aid use in the general US popu-
lation found that 5.3% of people aged 18–45 years34 and 8% 
of people aged 18–65 years35 used prescription medications 
at least once for sleep over the past year and 10% of individu-
als in both studies used over the counter medications.34,35 In 
another study of adults aged over 45 years with osteoarthritis 
and sleep difficulties, 17% used   prescription and 12% over 
the counter medications for sleep.36 In this study 36% of 
individuals reported using prescription or over the counter 
sleep medications at least 1–2 times a week. This suggests 
Table 2 sleep aid medication use
n (%)  Sleep problems  Sleep disturbance 
Prescription medications 
never use  331 (70.0) 32.4 ± 19.3a 27.9 ± 24.4a
,1/week  17 (3.6) 40.8 ± 18.4 39.3 ± 23.1
1–2 times/week  16 (3.4)  52.7 ± 16.3 56.5 ± 24.4
3–4 times/week  17 (3.6) 54.0 ± 20.2 56.0 ± 28.5
Every day  92 (19.5) 41.3 ± 19.7  39.9 ± 25.4
Over-the-counter medications 
never use  369 (78.0) 34.0 ± 19.7b 29.3 ± 24.7c
,1/week  28 (5.9) 31.9 ± 19.2 29.6 ± 21.6
1–2 times/week  17 (3.6) 52.1 ± 20.8 55.2 ± 27.4
3–4 times/week  22 (4.7) 43.1 ± 16.2 46.5 ± 23.7
Every day  37 (7.8) 45.5 ± 21.4 48.6 ± 28.4
Notes: sleep problems were measured using the MOss sleep Problems index ii subscale and sleep disturbance using the MOss sleep disturbance subscale. sometimes users 
were defined as those in the middle three categories (,1/week to 3–4 times/week). Wilcoxon rank sum tests were used for statistical comparisons and P-values ,0.004 
were considered significant due to Bonferroni adjustment for multiple tests. aScore is statistically significantly different compared to both sometimes users and every day 
users (all P , 0.0001). bScore is statistically significantly different compared to every day users (P = 0.002). cScore is statistically significantly different compared to sometimes 
(P = 0.002) and every day users (P , 0.0001).
Table 3 Multiple linear regression results examining statistically significant factors associated with sleep problems in MS (N = 465)
Final model adjusted R2 0.45
Model predictor Coefficient Standard 
error
Standardized 
beta coefficient
t-score P-value R2
contribution
Depression  1.47 0.23 0.33 6.51 ,0.001 0.329
Leg cramps  3.44 0.80 0.18 4.30 ,0.001 0.039
Age  -0.28 0.07 -0.15 -3.80 ,0.001 0.030
Pain  0.96 0.27 0.16 3.63 ,0.001 0.029
Female sex  4.44 1.69 0.08 2.63 0.009 0.005
Fatigue  0.15 0.06 0.13 2.41 0.016 0.008
Duration of Ms -0.19 0.09 -0.1 -2.29 0.023 0.005
nocturia  3.61 1.61 0.09 2.24 0.025 0.004
Notes: The sleep problems outcome was defined using the Sleep Problems Index II subscale of the MOSS Scale.
Abbreviations: MOss, Medical Outcomes study sleep; Ms, multiple sclerosis.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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that a considerably larger percentage of individuals   reporting 
sleep difficulties with MS are using pharmaceutical sleep aids 
than the level reported in the general population, though this 
level is similar to use in the osteoarthritis population with 
sleep problems. The results indicate that patients with MS, 
and possibly their health care providers, may be more aware 
of the need for therapeutic sleep, or, alternatively, that patients 
with MS have greater problems with sleep. More research is 
needed to better understand why people with MS who expe-
rience sleep problems use or do not use medications and to 
understand what nonpharmacological strategies people may 
be employing.
In order to identify factors in addition to fatigue that 
may play a role in sleep disorders in the MS population, we 
completed a multiple linear regression to explore the role of 
multiple factors, identified through both the MS and general 
sleep literature, on sleep problems in this population. Our 
results suggest that there are a number of factors (depression, 
pain, leg cramps, fatigue, and nocturia) that may contribute 
to sleep problems in MS that are potentially modifiable, and 
when treated could improve sleep in MS patients. In addition, 
our results indicate that of these, depression is most highly 
associated with sleep difficulties. This suggests that, as is the 
case in the general population, treatment of sleep problems 
should be considered in concert with treatment for depres-
sion, and that individuals with MS and depression should be 
assessed for sleep disorders by their treating physician. This 
finding is also significant in that the substantial majority of 
the research on sleep in MS has focused on the relationship 
between fatigue and sleep. However, our results suggest that 
fatigue may play less of a role in sleep than previously thought, 
and that other factors, such as depression, leg cramps, and 
pain management, should be addressed by physicians and 
patients in discussions related to sleep difficulties. Surpris-
ingly, restless leg symptoms were not associated with sleep 
problems, even though about 50% of persons reported restless 
leg symptoms. However, leg cramps may explain much of the 
same variance in sleep problems as restless legs because a uni-
variate regression of restless legs was statistically   significant. 
Thus, both leg cramps and restless legs should be discussed 
by patients and physicians when addressing factors that may 
significantly impact the patient’s sleep.
Identifying factors associated with sleep in MS is of key 
importance as sleep disorders are known to have an impact on 
mental health, overall physical health, quality of life, and have 
been related to lower work productivity and higher utilization 
of health care services.5,6 Additionally, sleep may be even more 
important for people with MS as recent research suggests that 
sleep is needed for the optimization of brain function   following 
plasticity. Some sleep research suggests that slow wave sleep 
is necessary to downscale the synaptic strength of new brain 
circuits resulting from the plastic process to a baseline level that 
is energetically sustainable, and is also beneficial for learning 
and memory.37 This plasticity is necessary for MS patients to 
maintain both physical and mental function as their disease 
progresses and occurs as a compensatory mechanism as neu-
ral loss progresses in the central nervous system in persons 
with MS.38 Thus, this research suggests that sleep may play a 
significant role in maintaining function in MS and may have 
impacts beyond those seen in other chronically ill or disability 
populations because of the critical role plasticity plays for 
maintaining function. However, more research is needed to 
explore this hypothesis.
Because this study was completed using cross-sectional 
data, the directional effects of the significant predictors on 
sleep cannot be determined. For example, we cannot say 
that depression causes sleep problems, only that they are 
significantly associated and that they occur together in this 
study population. Future research (eg, clinical trials, lon-
gitudinal studies) is needed to explore the causal nature of 
the relationships identified here and to examine what treat-
ments targeted to the specific factors associated with sleep 
difficulties would have the highest impact on reducing sleep 
problems in persons with MS. In addition, this study used 
self-reported data as the only source of information and 
did not include physician assessments or medical records. 
Therefore, we are only able to examine the relationships 
between self-reported symptoms rather than actual diag-
nostic outcomes such as insomnia disorder, sleep apnea, 
or narcolepsy with   objective assessment by tools such as 
polysomnography. Thus, our conclusions can only generally 
inform decisions about treatment of these specific disorders 
and future research is needed to determine which factors are 
significantly associated with each type of sleep disorder. The 
sleep problems index outcome used in this study is generally 
though to most closely measure the construct of insomnia, 
though includes other items related to sleep disordered 
breathing and narcolepsy. Because fatigue and depression 
have been found to commonly co-exist in individuals in this 
population and may be causally related, we also investigated 
the potential for a fatigue–depression interaction effect in our 
model. Though this interaction was not statistically significant 
in our final model, this may be due to the fact that power 
to detect interaction effects is lower than power to detect 
main effects. Future studies related to sleep in MS should 
continue to consider the potential interaction of fatigue and Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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depression. Lastly, because this study was completed using 
data collected at one time during a longitudinal study, the 
representativeness of the study population has some bias. 
For example, though dropout was minimal over the course 
of the four surveys, there was some attrition and individuals 
who dropped out of the study tended to have more depression 
and pain than those who remained in the study. Thus, this 
sample is likely to be less depressed and have less pain than 
the general population of persons with MS.
To the best of our knowledge, this is the first paper to look 
at the problem of inadequate sleep in the MS population and 
medication use related to sleep. In our study we have identified 
a number of factors associated with poor sleep, and challenged 
the popular conception that fatigue is the most important 
factor related to poor sleep in this population. Considering that 
persons with MS have a progressive neurological condition 
affecting their central nervous system, and that neural loss 
and brain atrophy appear to be, to some extent, independent 
of conventional and available disease modifying treatments, it 
is vital in the management of this disease that all therapeutic 
measures possible be addressed to optimize brain function and 
plasticity. In addition, there is little evidence in the literature 
with respect to the efficacy of over the counter or prescription 
sleep aids for people with MS and there may be consequences 
in terms of suppression of slow-wave sleep for various phar-
macological sleep aids.39 Given that tricyclic antidepressants 
can be used to improve sleep and treat depression, and the sig-
nificant finding here with respect to the relationship between 
sleep problems and depression, further research on the use 
of TCAs and other depression treatments in MS may be war-
ranted. In addition to pharmacological approaches, there is 
also emerging evidence of the efficacy of self management40 
and cognitive behavioral therapy41,42 to enhance sleep, and 
research into the application of these techniques to people 
with MS seems desirable due to the potential lack of efficacy 
and side effects43 of sleep pharmaceutics and their potential 
interruption of slow wave sleep cycles.
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